309 related articles for article (PubMed ID: 38504070)
21. Targeting endothelial cell metabolism in cancerous microenvironment: a new approach for anti-angiogenic therapy.
Mohammadi P; Yarani R; Rahimpour A; Ranjbarnejad F; Mendes Lopes de Melo J; Mansouri K
Drug Metab Rev; 2022 Nov; 54(4):386-400. PubMed ID: 36031813
[TBL] [Abstract][Full Text] [Related]
22. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.
Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B
Front Immunol; 2020; 11():1956. PubMed ID: 32983126
[TBL] [Abstract][Full Text] [Related]
23. Supramolecular Polymer-Nanomedicine Hydrogel Loaded with Tumor Associated Macrophage-Reprogramming polyTLR7/8a Nanoregulator for Enhanced Anti-Angiogenesis Therapy of Orthotopic Hepatocellular Carcinoma.
Liu X; Huangfu Y; Wang J; Kong P; Tian W; Liu P; Fang C; Li S; Nie Y; Feng Z; Huang P; Shi S; Zhang C; Dong A; Wang W
Adv Sci (Weinh); 2023 Aug; 10(22):e2300637. PubMed ID: 37229748
[TBL] [Abstract][Full Text] [Related]
24. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
Abdollahi A; Folkman J
Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
[TBL] [Abstract][Full Text] [Related]
25. A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors.
Shimamura M; Nagasawa H; Ashino H; Yamamoto Y; Hazato T; Uto Y; Hori H; Inayama S
Br J Cancer; 2003 Jan; 88(2):307-13. PubMed ID: 12610518
[TBL] [Abstract][Full Text] [Related]
26. [Advances in mechanism of traditional Chinese medicine in inhibiting angiogenesis in ovarian cancer].
Tang MY; Ding DN; Xie YY; Shen F; Li J; Liu FY; Han FJ
Zhongguo Zhong Yao Za Zhi; 2023 Dec; 48(24):6572-6581. PubMed ID: 38212017
[TBL] [Abstract][Full Text] [Related]
27. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
28. Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy.
Yetkin-Arik B; Kastelein AW; Klaassen I; Jansen CHJR; Latul YP; Vittori M; Biri A; Kahraman K; Griffioen AW; Amant F; Lok CAR; Schlingemann RO; van Noorden CJF
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188446. PubMed ID: 33058997
[TBL] [Abstract][Full Text] [Related]
29. Amino acid transporter LAT1 in tumor-associated vascular endothelium promotes angiogenesis by regulating cell proliferation and VEGF-A-dependent mTORC1 activation.
Quan L; Ohgaki R; Hara S; Okuda S; Wei L; Okanishi H; Nagamori S; Endou H; Kanai Y
J Exp Clin Cancer Res; 2020 Nov; 39(1):266. PubMed ID: 33256804
[TBL] [Abstract][Full Text] [Related]
30. Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy.
Elebiyo TC; Rotimi D; Evbuomwan IO; Maimako RF; Iyobhebhe M; Ojo OA; Oluba OM; Adeyemi OS
Cancer Treat Res Commun; 2022; 32():100620. PubMed ID: 35964475
[TBL] [Abstract][Full Text] [Related]
31. Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer.
Choi SH; Yoo SS; Lee SY; Park JY
Arch Pharm Res; 2022 Apr; 45(4):263-279. PubMed ID: 35449345
[TBL] [Abstract][Full Text] [Related]
32. The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment.
Li D; Finley SD
Integr Biol (Camb); 2018 Apr; 10(4):253-269. PubMed ID: 29623971
[TBL] [Abstract][Full Text] [Related]
33. Oncometabolites lactate and succinate drive pro-angiogenic macrophage response in tumors.
Kes MMG; Van den Bossche J; Griffioen AW; Huijbers EJM
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188427. PubMed ID: 32961257
[TBL] [Abstract][Full Text] [Related]
34. Multiprong control of glioblastoma multiforme invasiveness: blockade of pro-inflammatory signaling, anti-angiogenesis, and homeostasis restoration.
Bazan NG; Reid MM; Flores VAC; Gallo JE; Lewis W; Belayev L
Cancer Metastasis Rev; 2021 Sep; 40(3):643-647. PubMed ID: 34519960
[TBL] [Abstract][Full Text] [Related]
35. The Sabotaging Role of Myeloid Cells in Anti-Angiogenic Therapy: Coordination of Angiogenesis and Immune Suppression by Hypoxia.
Li C; Liu T; Bazhin AV; Yang Y
J Cell Physiol; 2017 Sep; 232(9):2312-2322. PubMed ID: 27935039
[TBL] [Abstract][Full Text] [Related]
36. The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer - New Combinational Approaches and Strategies of Neovessel Inhibition.
Daum S; Hagen H; Naismith E; Wolf D; Pircher A
Front Cell Dev Biol; 2020; 8():610903. PubMed ID: 33469537
[TBL] [Abstract][Full Text] [Related]
37. Exosomal EPHA2 derived from highly metastatic breast cancer cells promotes angiogenesis by activating the AMPK signaling pathway through Ephrin A1-EPHA2 forward signaling.
Han B; Zhang H; Tian R; Liu H; Wang Z; Wang Z; Tian J; Cui Y; Ren S; Zuo X; Tian R; Niu R; Zhang F
Theranostics; 2022; 12(9):4127-4146. PubMed ID: 35673569
[No Abstract] [Full Text] [Related]
38. Current status and future of anti-angiogenic drugs in lung cancer.
Yan X; Zhao Z; Tang H
Clin Exp Med; 2023 Oct; 23(6):2009-2023. PubMed ID: 36920592
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic application of anti-angiogenic nanomaterials in cancers.
Mukherjee S; Patra CR
Nanoscale; 2016 Jul; 8(25):12444-70. PubMed ID: 27067119
[TBL] [Abstract][Full Text] [Related]
40. Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives.
Shang B; Cao Z; Zhou Q
Front Med; 2012 Mar; 6(1):67-78. PubMed ID: 22460450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
